Incyte (NASDAQ:INCY) Stock Price Target Raised at Royal Bank Of Canada

Incyte (NASDAQ:INCY) had its target price hoisted by research analysts at Royal Bank Of Canada from $114.00 to $117.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada‘s price objective indicates a potential downside of 3.29% from the company’s current price.

A number of other research analysts have also recently commented on INCY. BMO Capital Markets reissued a “market perform” rating on shares of Incyte in a research note on Tuesday. Stifel Nicolaus raised their target price on Incyte from $145.00 to $157.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Wall Street Zen downgraded shares of Incyte from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Benchmark restated a “buy” rating on shares of Incyte in a research report on Tuesday, October 13th. Finally, Weiss Ratings lowered Incyte from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, October 23rd. Twelve research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $132.95.

Incyte Stock Up 3.6%

Shares of Incyte stock traded up $4.18 on Friday, reaching $120.98. The company’s stock had a trading volume of 1,002,088 shares, compared to its average volume of 1,729,539. The firm’s fifty day simple moving average is $120.62 and its two-hundred day simple moving average is $108.07. The company has a market capitalization of $24.52 billion, a price-to-earnings ratio of 15.38, a P/E/G ratio of 4.83 and a beta of 0.74. Incyte has a 52 week low of $89.25 and a 52 week high of $132.60.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a return on equity of 29.93% and a net margin of 27.71%. The business had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. During the same quarter in the prior year, the business posted $2.26 EPS. Incyte’s revenue for the quarter was up 14.0% compared to the same quarter last year. As a group, research analysts predict that Incyte will post 1.97 EPS for the current year.

Insider Buying and Selling

In other news, insider Pablo Cagnoni sold 2,642 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $112.71, for a total value of $297,779.82. Following the completion of the sale, the insider owned 183,200 shares of the company’s stock, valued at $20,648,472. This represents a 1.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 16.20% of the company’s stock.

Institutional Trading of Incyte

A number of large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Incyte during the 2nd quarter valued at approximately $2,044,189,000. Legal & General Group Plc acquired a new position in shares of Incyte in the 2nd quarter valued at about $182,054,000. Caisse de depot et placement du Quebec acquired a new position in Incyte in the 2nd quarter worth about $155,360,000. Deutsche Bank AG bought a new position in shares of Incyte during the 2nd quarter valued at $143,172,000. Finally, Bank of New York Mellon Corp acquired a new position in Incyte during the second quarter valued at approximately $110,279,000. 96.97% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Barclays raised its price target on Incyte from $139 to $143 and maintained an “overweight” rating, implying substantial upside from recent levels. Barclays analyst rating
• Positive Sentiment: Third-quarter revenue beat expectations. Incyte reported $1.56 billion in total revenue, up 14% year over year and above the $1.46 billion analyst consensus. Product demand was broad-based: Jakafi and Jakafi XR sales rose 4% to $827 million, Opzelura sales increased 36% to $255 million, and hematology and oncology portfolio sales climbed 38% to $235 million. Incyte Q3 results
• Positive Sentiment: Management increased its 2026 outlook. Full-year net-sales guidance was raised to $5.21 billion-$5.30 billion from $5.13 billion-$5.26 billion previously, while Opzelura guidance was lifted to $1.10 billion-$1.12 billion. The stronger outlook reinforces expectations for continued commercial momentum. Incyte raises 2026 guidance
• Neutral Sentiment: Analyst views remain mixed. One Seeking Alpha analysis upgraded Incyte to “hold,” arguing that recent ESMO-related developments had largely closed the valuation gap, while other analysts—including Barclays and Guggenheim—remain constructive. Incyte valuation analysis
• Negative Sentiment: Incyte posted a quarterly loss after recording a $1.23 billion in-process research and development charge tied to its Vega Therapeutics acquisition. The company reported a loss of $3.60 per share, although this was narrower than analysts expected and largely reflected the acquisition accounting charge. Incyte Q3 acquisition charge

About Incyte

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.